Clinical Trials on Aspergillosis in United States

Total 67 results

Baylor Research Institute

Withdrawn

Benralizumab in the Treatment of Patients With Severe Asthma With ABPA

Severe Asthma | Allergic Bronchopulmonary Aspergillosis | ABPA

United States
Astellas Pharma Inc

Withdrawn

A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis

Aspergillosis/Blood | Aspergillosis/Invasive

United States
University of Pittsburgh
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis

Cystic Fibrosis | Allergic Bronchopulmonary Aspergillosis

United States
University of Pittsburgh
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA (ABPA)

Cystic Fibrosis | Allergic Bronchopulmonary Aspergillosis

United States
Zambon SpA

Completed

Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects

Allergic Bronchopulmonary Aspergillosis

United Kingdom
Pulmatrix Inc.

Terminated

Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis

Allergic Bronchopulmonary Aspergillosis

United States, Australia, United Kingdom, India, Poland
University of Alabama at Birmingham
University of Colorado, Denver

Completed

Immune Profiles in CF Fungal Infection

Fungal Infection | Cystic Fibrosis | Allergic Bronchopulmonary Aspergillosis

United States
F2G Biotech GmbH
Quotient Clinical

Completed

Evaluation of Immediate Release Tablet

Invasive Aspergillosis

United Kingdom
F2G Biotech GmbH
Hammersmith Medicines Research

Completed

Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe

Invasive Aspergillosis

United Kingdom
Community Pharmacology Services Ltd
Pulmatrix Inc.

Withdrawn

Allergic Bronchopulmonary Aspergillosis Prescreening Study

Asthma | Allergic Bronchopulmonary Aspergillosis | ABPA

United Kingdom
F2G Biotech GmbH
Quotient Clinical

Withdrawn

Radiolabelled IV and Oral Metabolism Study of F901318 (ADME)

Invasive Aspergillosis

United Kingdom
F2G Biotech GmbH
Simbec Research

Completed

F901318 Single Ascending Dose Study in Healthy Male Volunteers

Invasive Aspergillosis

United Kingdom
Regeneron Pharmaceuticals
Sanofi

Completed

Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)

Allergic Bronchopulmonary Aspergillosis

United States, Hungary, Bulgaria, France, Germany, Japan, Netherlands, Poland, Romania, United Kingdom
F2G Biotech GmbH
Celerion Ltd

Completed

Study of Potential for Interaction of Fluconazole With F901318

Invasive Aspergillosis

United Kingdom
F2G Biotech GmbH
Simbec-Orion Group

Completed

Single Ascending Oral Dose Study of F901318

Invasive Aspergillosis

United Kingdom
F2G Biotech GmbH
Hammersmith Medicines Research

Completed

F901318 Multiple Ascending Dose Study

Invasive Aspergillosis

United Kingdom
Pfizer

Terminated

A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children

Invasive Aspergillosis

Spain, United States, Singapore, Canada, Czechia, Netherlands, Poland, Thailand
F2G Biotech GmbH
Covance

Completed

Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects

Invasive Aspergillosis

United Kingdom
F2G Biotech GmbH
SimbecRresearch Ltd.

Completed

Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects (ORALMAD)

Invasive Aspergillosis

United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants

Invasive Aspergillosis | Invasive Mucormycosis

United States, Belgium, Spain
Merck Sharp & Dohme LLC

Completed

Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)

Invasive Aspergillosis

Belgium, United States, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Peru, Russian Federation
Scynexis, Inc.

Completed

Study to Evaluate the Safety and Efficacy of the Coadministration of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis (SCYNERGIA)

Invasive Pulmonary Aspergillosis

United States, Belgium, Canada, Germany, South Africa
Vical

Terminated

VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

Invasive Aspergillosis | Invasive Pulmonary Aspergillosis

United States, Korea, Republic of, Canada, Belgium, France, Germany
F2G Biotech GmbH
Iqvia Pty Ltd; Shionogi

Recruiting

Olorofim Aspergillus Infection Study (OASIS)

Invasive Aspergillosis

United States, Taiwan, Belgium, Spain, Italy, Turkey, New Zealand, China, Canada, Netherlands, Australia, Brazil, Singapore, Israel, France, Thailand, Germany, Japan, Korea, Republic of, United Kingdom
Pfizer

Completed

Patterns of Real-World Isavuconazole Use - a Study of Patients With Mucormycosis or Invasive Aspergillosis (PRISMA)

Mucormycosis | Invasive Aspergillosis

Spain, Germany, France, United Kingdom, Italy
Arkansas Children's Hospital Research Institute
National Institute of Allergy and Infectious Diseases (NIAID); Children's Hospital...

Recruiting

Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections (DOMINIC)

Pulmonary Invasive Fungal Infections | Pulmonary Invasive Aspergillosis

United States, Canada
St George's University Hospitals NHS Foundation...
University College, London; St George's, University of London; University of... and other collaborators

Recruiting

LFD of Aspergillus Antigen in Paediatrics (LFD-AsPaeds)

Invasive Pulmonary Aspergillosis | Invasive Fungal Disease

United Kingdom
Jeffrey Jenks, MD, MPH
Astellas Pharma Global Development, Inc.

Terminated

Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis (Isavu-CAPA)

Severe Acute Respiratory Syndrome Coronavirus 2 | Aspergillosis Invasive

United States
Novartis Pharmaceuticals

Terminated

An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)

Cystic Fibrosis | Allergic Bronchopulmonary Aspergillosis

United Kingdom, Germany, Belgium, Italy, Netherlands
National Cancer Institute (NCI)

Completed

Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis

Invasive Pulmonary Aspergillosis | Immunocompromised Host | Invasive Pulmonary Fungal Infection | Invasive Pulmonary Zygomycosis

United States
Pulmatrix Inc.

Terminated

Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

ABPA

Australia, United States, United Kingdom, France
University of Arkansas

Withdrawn

Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis

Aspergillosis

United States
King's College Hospital NHS Trust

Completed

Diagnostic and Management Strategies for Invasive Aspergillosis

Neutropenia | Invasive Aspergillosis

United Kingdom
Pulmocide Ltd

Recruiting

Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)

Refractory IPA

Spain, United States, Canada, Italy, Austria, France, Israel, United Kingdom, Belgium, Korea, Republic of, Brazil, Germany, Chile, Greece, Taiwan, Argentina, Colombia
Pfizer
Vicuron Pharmaceuticals

Completed

A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).

Aspergillosis

United States
Pulmocide Ltd

Completed

A Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)

Pulmonary Aspergillosis

United States, Canada
Pfizer

Terminated

Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)

Aspergillosis

United States
University of Pittsburgh
National Center for Research Resources (NCRR)

Completed

Voriconazole Prophylaxis Against Aspergillosis in Lung Transplant Recipients

Post Lung Transplantation

United States
Astellas Pharma Inc

Terminated

Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis

Aspergillosis

United States
National Cancer Institute (NCI)

Completed

Voriconazole to Prevent Systemic Fungal Infections in Children

Mycoses | Candidiasis | Aspergillosis | Fungal Diseases

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Natural History of Individuals With Immune System Problems That Lead to Fungal Infections

Invasive Aspergillosis | Chronic Mucocutaneous Candidiasis | CARD9 | APECED

United States
Scynexis, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)

Coccidioidomycosis | Invasive Pulmonary Aspergillosis | Allergic Bronchopulmonary Aspergillosis | Histoplasmosis | Chronic Pulmonary Aspergillosis | Blastomycosis | Invasive Candidiasis | Recurrent Vulvovaginal Candidiasis | Mucocutaneous Candidiasis | Other Emerging Fungi

United States, Spain, United Kingdom, Austria, Pakistan, South Africa, Germany, Netherlands
Brynn Chappell
The Christie NHS Foundation Trust

Suspended

Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy (PIVOTAL)

Aspergillosis | Immunocompromised Patient | Fusarium

United Kingdom
University of Alabama at Birmingham
Astellas Pharma Inc; Centers for Disease Control and Prevention

Completed

COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI) (CAPA IFI)

Covid19 | Fungal Infection | Aspergillosis

United States
Astellas Pharma Inc

Completed

Study of FK463 for the Treatment of Invasive Aspergillosis

Aspergillosis

United Kingdom, Austria, France, Germany, Italy, Poland, Spain, Sweden
Pfizer

Completed

Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis

Aspergillosis

United States, Australia, Canada, Greece, Belgium, Germany, Korea, Republic of, Poland, Russian Federation, Spain, Turkey, Thailand, Brazil, Czech Republic, France, India, Italy, Netherlands, Peru, Portugal, Singapore, Switzerland, ... and more
Pfizer

Completed

A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects

Candidemia | Aspergillosis

United States
National Cancer Institute (NCI)

Completed

Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients

Mycoses | Candidiasis | Fungemia | Aspergillosis

United States
National Cancer Institute (NCI)

Completed

An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections

Mycoses | Candidiasis | Fungemia | Aspergillosis

United States
Pulmocide Ltd

Terminated

The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases

Bronchiectasis | Asthma | COPD | Respiratory Candidiasis | Respiratory Aspergillosis

United Kingdom

Clinical Trials on Aspergillosis in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations